Gastrointestinal (GI): NSAIDs that block COX-1 activity have correlations with GI complications due to the inhibition of your synthesis of gastroprotective agents including PGE2 as well as other prostaglandins. This inhibition leads to decreased mucin output by gastric epithelial cells, a lot less bicarbonate secretion, and less epithelial mobile turnover, https://glenny421kry9.blogmazing.com/profile